Lisata Therapeutics, Inc.
LSTA
$1.09
-$0.04-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 100.00K | 170.00K | 170.00K | 1.07M | 1.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.00K | 170.00K | 170.00K | 1.07M | 1.07M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 100.00K | 170.00K | 170.00K | 1.07M | 1.07M |
| SG&A Expenses | 11.65M | 10.92M | 10.43M | 11.38M | 11.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.53M | 17.47M | 18.38M | 21.15M | 22.07M |
| Operating Income | -16.43M | -17.30M | -18.21M | -20.08M | -21.00M |
| Income Before Tax | -15.01M | -16.74M | -17.55M | -19.20M | -19.89M |
| Income Tax Expenses | -387.00K | -387.00K | -962.00K | -962.00K | -962.00K |
| Earnings from Continuing Operations | -14.62 | -16.35 | -16.59 | -18.24 | -18.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.62M | -16.35M | -16.59M | -18.24M | -18.92M |
| EBIT | -16.43M | -17.30M | -18.21M | -20.08M | -21.00M |
| EBITDA | -16.36M | -17.20M | -18.06M | -19.91M | -20.83M |
| EPS Basic | -1.64 | -1.86 | -1.91 | -2.13 | -2.23 |
| Normalized Basic EPS | -1.05 | -1.19 | -1.27 | -1.40 | -1.47 |
| EPS Diluted | -1.64 | -1.86 | -1.91 | -2.13 | -2.23 |
| Normalized Diluted EPS | -1.05 | -1.19 | -1.27 | -1.40 | -1.47 |
| Average Basic Shares Outstanding | 35.65M | 35.15M | 34.75M | 34.34M | 33.92M |
| Average Diluted Shares Outstanding | 35.65M | 35.15M | 34.75M | 34.34M | 33.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |